experiment in vitro E in vivo The combination with Priteptidase showed more effective efficacy than the drug Remdesivir, which is the only antiviral drug approved for the treatment of COVID-19. PharmaMar, the company that produces the drug in Spain, is negotiating more trials to study its efficacy.
The latest investigation report science show Lipase Managed to greatly reduce the virus load SARS-CoV-2 In human cell models and mice.
The results show that in these Preclinical model, This drug is more resistant to covid-19 than Redesivir, Is the only antiviral drug that has been approved for the treatment of this disease. The manufacturer of the Spanish pharmaceutical company PharmaMar has promised that it will study the efficacy of its anti-covid therapy through tests in humans. The third phase.
Lipopeptin is an active substance Anti-oncogene From sea squirt (Eco white) Causes the destruction of tumor cells through a process called apoptosis.The drug has been evaluated as an anti-tumor drug for different types of cancer, mainly for Multiple myelomaExplain that the professors of pharmacology Francisco López-Muñoz and José Antonio Guerra in conversation.
The antiviral activity of alicycline is by acting on eEF1A protein, Exists in human cells and is used by coronaviruses to multiply and infect other cells.The strategy of other antiviral drugs (such as remdesivir) is to “attack” the protein of the virus itself, which is more likely twist Therefore becomes Resistant.
In this study, alicycline showed anti-coronavirus activity 27.5 times more powerful In remdesivir Human cell in vitro.Therefore, the article points out that lipoprotein in vitro Demonstrated “powerful Antiviral efficacyCompared with other anti-SARS-CoV-2 antiviral drugs, the toxicity is limited.
At the same time, the researchers tested the drug mouse Infected with SARS-CoV-2. Compared with the control group, rodents that received the active ingredient could preventively reduce their viral load and lung inflammation.In two different animal models of SARS-CoV-2 infection, the assay showed that virus replication was reduced, resulting in Viral load reduced by 99% In the lungs of animals treated with lipoproteinases.
Research points out that despite toxicity In any antiviral drugs targeting human cell proteins, Safety Platts pepsin is already very mature in humans. The tolerated dose of the drug used in Pharmamar’s clinical trials was significantly lower than the dose used in these preclinical model trials.
PharmaMar clinical trial
Published concurrently with this research science, The pharmaceutical company PharmaMar is launching Clinical trials in patients with covid-19 People who need to be hospitalized This trial is designed to assess the safety and toxicity profile, as well as the new efficacy of Pritazin.
After the results of these experiments are published in vivo E in vitro, PharmaMar ensured negotiations with different regulatory agencies on planned phase III clinical trials.
This publication is the result of a collaboration between PharmaMar and the laboratory of Kris White, Adolfo García-Sastre and Thomas Zwaka, Department of Microbiology and Cell, Regenerative and Developmental Biology, Icahn School of Medicine. In a statement, the pharmacist detailed Kevan Shokat and Nevan Krogan of the Institute of Quantitative Biological Sciences of the University of California, San Francisco, and Marco Vignuzzi of the Pasteur Institute in Paris.